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SeleniumBackground: Pregnancy-induced hypertensive disorders (PIHD), including preeclampsia, cause maternal and
perinatal morbidity and mortality worldwide. Several studies have linked selenium supplementation and sele-
nium status to the risk of preeclampsia, but there are no published prospective population-based studies exam-
ining associations between dietary selenium intake and preeclampsia.
Aim: To examine associations between selenium intake from diet and supplements and selenium blood status
and PIHD incidence, with sub-analyses for pregnancy-induced hypertension (PIH) and preeclampsia, in a large
pregnancy cohort.
Method: The study is based on 69,972 singletonpregnancies from theNorwegianMother, Father andChild Cohort
Study. Maternal dietary selenium intake was assessed with a validated, semi-quantitative food frequency ques-
tionnaire at about gestational week 22. Maternal selenium concentrations were measured in whole blood col-
lected around gestational week 18 in a subset of 2572 women. Preeclampsia and PIH diagnosges were
obtained from the Medical Birth Registry of Norway.ncy questionnaire; MoBa, the Norwegian Mother, Father and Child Cohort Study; PIH, pregnancy-induced hypertension; PIHD,
sed controlled trial; RDI, recommended daily intake; Se, selenium.
lgrenska University Hospital, Department of Obstetrics and Gynaecology, Gothenburg, Sweden.
piel).
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
E. Holmquist, A.L. Brantsæter, H.M. Meltzer et al. Science of the Total Environment 798 (2021) 149271Selenium supplementation
The Norwegian mother, father and child cohort
study
MoBaResults: Participants had amedian dietary selenium intake of 53 μg/day (IQR 44–62). Dietary selenium intakewas
not significantly associated with PIHD (adjusted (a) OR 1.03, 95% CI 0.98, 1.08 per SD of selenium intake), pre-
eclampsia or PIH. Threshold analyses for deciles of dietary selenium intake did not show any significant associa-
tions. Neither inorganic (aOR 1.01, 95% CI 0.98, 1.05) or organic selenium supplement intake (aOR 0.98, 95% CI
0.95, 1.02) or selenium blood status was significantly associated with PIHD (aOR 1.03, 95% CI 0.86, 1.22) or
PIHD subgroups.
Conclusion: No significant associations were found between reported selenium intake from diet, or dietary sup-
plements or whole-blood selenium status and PIHD in general or preeclampsia specifically. Hence, the results of
this large population-based study, with selenium intake close to the recommended daily intake, do not support
previous findings indicating a possible protective effect of selenium supplementation or selenium statuswith re-
gard to preeclampsia incidence.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Pregnancy-induced hypertensive disorders (PIHD) are themost com-
monmedical complication of pregnancy, affecting 10–15%of all pregnan-
cies worldwide (Magee et al., 2015; Malik and Kumar, 2017; Shah and
Gupta, 2019). PIHD include pregnancy-induced hypertension (PIH), de-
fined as onset of hypertension (blood pressure > 140/90) after 20
weeks of gestation in previously normotensive women; and preeclamp-
sia, diagnosed when hypertension and significant proteinuria develop
after gestational week 20 (Shah and Gupta, 2019). Preeclampsia at the
time of the current study was defined as severe when organs are signifi-
cantly affected or when blood pressure exceeds 160/110 in association
with proteinuria (Baha Sibai, 2005; Shah and Gupta, 2019). Preeclampsia
affects 2–7% with regional differences and higher incidence in primipa-
rous women (Baha Sibai, 2005; Burton et al., 2019). It is a major cause
of maternal morbidity and mortality, as well as of perinatal death, pre-
term delivery and intrauterine growth restriction (Baha Sibai, 2005).
Preeclampsia is a multisystem disorder, commonly regarded as a
state of oxidative stress (Mistry et al., 2008). Genetic, immunological
and other factors, such as pre-existing maternal chronic diseases, are
considered to interact in the modelling of inadequate spiral arterioles
and abnormal placentation characterising early preeclamptic pregnan-
cies. This leads to increased systemic vascular resistance, enhanced
platelet aggregation, activation of the coagulation system and endothe-
lial cell dysfunction (Baha Sibai, 2005; Burton et al., 2019; Mistry et al.,
2008; Rana et al., 2019). Despite extensive research over the years, no
breakthrough in prediction or prevention has as yet occurred, except
administration of acetylsalicylic acid to women at risk (Roberge et al.,
2018; Sibai, 1998). This treatment is, however, associated with in-
creased risk of intrapartum bleeding, neonatal intracranial haemor-
rhage and postpartum haemorrhage (Hastie et al., 2021).
Selenium is an essential trace element for humans originating from
soil (Combs, 2001). In Europe, selenium intake has declined as a conse-
quence of collapse in import of US wheat, and suboptimal selenium in-
take has been documented in many European countries (Barman et al.,
2020; Stoffaneller and Morse, 2015). Selenium, incorporated into
seleno-proteins, has been found to influence inflammatory response
and to protect against oxidative stress, both components in a pregnancy
complicated by PIHD (Bizerea et al., 2018; Chamy et al., 2006; Khera
et al., 2013; Rayman, 2009; Roman et al., 2014; Watson et al., 2012).
Several studies have examined the potential protective role of selenium
supplementation with regard to PIHD (Ghaemi et al., 2013; Han and
Zhou, 1994; Mistry et al., 2015; Rayman et al., 2015; Rayman et al.,
2003; Rayman et al., 2014; Tara et al., 2010). Some randomised con-
trolled trials (RCT) have indicated beneficial effects of selenium supple-
mentation on preeclampsia and PIH (Han and Zhou, 1994; Rayman
et al., 2015; Rayman et al., 2014), while others have not (Tara et al.,
2010) (see Table 1).
Studies in different global regions have found that a plasma sele-
nium concentration ≥ 95 μg/L correlates with a lower preeclampsia inci-
dence (Vanderlelie and Perkins, 2011). Decreased preeclampsia2
incidence was found in Finland and New Zeeland after introduction of
routine selenium supplementation through soil enrichment (Thomson
and Robinson, 1996; Vanderlelie and Perkins, 2011; Wang et al.,
1998). Some case-control studies, e.g., a study from the UK and a preg-
nancy cohort study from Poland, reported significant associations be-
tween higher selenium levels during pregnancy and decreased
incidence of preeclampsia (Atamer et al., 2005; Ghaemi et al., 2013;
Lewandowska et al., 2019; Maleki et al., 2011; Rayman et al., 2003),
while others did not find this association (da Silva et al., 2017; Mistry
et al., 2015) (Table 2).
To the best of our knowledge, no prospective population-based
study on associations between dietary selenium intake and PIHD has
as yet been performed. The NorwegianMother, Father and Child Cohort
study (MoBa), comprising detailed information on dietary selenium in-
take based on a validated food frequency questionnaire (FFQ) and com-
prehensive information on lifestyle and social and medical risk factors,
offers a unique possibility to study such associations. The aim of this
study was to examine the associations between selenium intake from
diet and supplements and the incidence of PIHD such as PIH and pre-
eclampsia. In addition, we also examined the association between
whole-blood selenium status and the incidence of these outcomes in a
sub-group within the cohort.
2. Material and methods
2.1. Study population
This study is based on data fromMoBa and the Medical Birth Regis-
try of Norway (MBRN). MoBa is a prospective population-based preg-
nancy cohort study conducted by the 08 (Magnus et al., 2016). The
MBRN is a national health registry containing information about all
births in Norway. Participants were recruited from all over Norway
from 1999 to 2008. Consent to participate was granted in 41% of the
pregnancies in which invitations were provided. The cohort includes
114,500 children, 95,200 mothers and 75,200 fathers (Magnus et al.,
2016). Pregnant womenwere invited by postal invitation in connection
with the routine ultrasound scan offered free of charge to all women at
gestational week 18. They were asked to answer three questionnaires
during pregnancy and to provide blood and urine samples at the time
of the scan. Participants were followed up regularly with questionnaires
after delivery (Magnus et al., 2016). This study is based on information
from the first questionnaire (Q1) about general health and lifestyle,
filled out around gestational week 15, and the second questionnaire
(Q2), a semi-quantitative food frequency questionnaire (FFQ) devel-
oped specifically for MoBa and used from 2002 onward. The FFQ was
answered around gestational week 22 and asked about average intake
of food and dietary supplements since the start of pregnancy (Meltzer
et al., 2008).
This study is based on version 10 of the quality-assured data files re-
leased for research in 2017. Informed consent was obtained from each
MoBa participant upon recruitment.
Table 1
Studies on associations between selenium supplementation and pregnancy-induced hypertensive disorders.
Ref (no) Author, title, journal and year of
publication






(Han and Zhou, 1994) Han et al. Selenium supplement in the
prevention of pregnancy- induced
hypertension. Chin Med J (Engl), 1994
Randomisation of women at high
risk of PIH: 52 were given Se 100
μg/d (natural dietetic liquid) and




Incidence of PIH was 7.7% in the
Se-treated group and 22.7% in the
placebo group, p < 0.05.
China
(Tara et al., 2010) Tara et al. Selenium supplementation and
the incidence of preeclampsia in pregnant
Iranian women: a randomized, double-
blind, placebo-controlled pilot trial. Taiwan
J Obstet Gynecol, 2010
Randomisation of 166 healthy
women to 100 μg Se/day (yeast)
or placebo, from first trimester to
delivery
Se in serum
122.5 ± 23.2 μg/L
(up to 12 weeks)
No significant difference (no incidence
of preeclampsia in the Se group,
compared with 4.7% (n = 3) in the
control group, p > 0.05)
Iran
(Rayman et al., 2014) Rayman et al. Effect of selenium on markers
of risk of pre-eclampsia in UK pregnant
women: a randomised, controlled pilot trial.
Br J Nutr, 2014
230 primiparas randomised to Se
60 μg/d (Se-enriched yeast) or
placebo, from 12 to 14 weeks of
gestation until delivery




Se treatment significantly reduced the
odds of either preeclampsia or PIH (OR
0.350, 95% CI 0.126, 0.974; p = 0.044).
Analyses were adjusted for baseline Se
concentration and haematocrit.
UK
(Rayman et al., 2015) Rayman et al. Selenium status in U.K.
pregnant women and its relationship with
hypertensive conditions of pregnancy. Br J
Nutr, 2015.





After exclusion of non-compliers with
Se treatment, Se supplementation was
found to significantly reduce the OR for
preeclampsia/PIH (OR 0.30, 95% CI 0.09,
1.00, p = 0.049)
UK
a Se = selenium; 1 μmol/L selenium × 79 = 1 μg/L; 80 μg/L plasma selenium equals ~100 μg/L whole blood selenium.
Table 2
Studies on associations between selenium status and pregnancy-induced hypertensive disorders.
Ref no Author, title, journal and year of publication Study design Outcome Country
(Rayman et al.,
2003)
Rayman et al. Low selenium status is associated
with the occurrence of the pregnancy disease
preeclampsia in women from the United
Kingdom. Am J Obstet Gynecol, 2003
Median toenail Se concentrations measured in
53 preeclamptic patients and 53 matched
pregnant controls (toenails laid down 3-12
months previously).
Significantly lower median toenail Se
concentrations in preeclamptic subjects than
in controls (p = 0.001). Within the
preeclamptic group, lower Se levels were





Atamer et al. Lipid peroxidation, antioxidant
defense, status of trace metals and leptin levels
in preeclampsia. Eur J Obstet Gynecol Reprod
Biol, 2005
In a cross-sectional, prospective study serum
Se levels were measured in 32 preeclamptic,
25 non-pregnant women and 28 pregnant
women without PIHD, all previously healthy.
Serum levels of Se were significantly lower (p
< 0.001) in preeclamptic women (60.68 ±
6.42 μg/L), compared to healthy women




Maleki et al. The relationship between plasma
level of Se and preeclampsia. Hypertens
Pregnancy, 2011
Plasma Se levels measured in 40 preeclamptic
and 40 healthy pregnant women at gestational
week 34-39.
Compared to the highest plasma Se tertile,
women in the lowest tertile (≤47 μg/L) and in
the middle tertile (≤58 μg/L) had significantly
increased risk of preeclampsia (OR 4.96; 95%





Ghaemi et al. A prospective study of selenium
concentration and risk of preeclampsia in
pregnant Iranian women: a nested case-control
study. Biol Trace Elem Res, 2013
Plasma Se concentrations were first measured
at gestational week 24-28 in a group of 650
healthy primiparous women. Measured again
3 months later in 38 women presenting with
preeclampsia and in nested matched controls
without preeclampsia.
Se plasma concentrations were significantly
lower in the case group (70.63 ± 21.41 versus
82.03 ± 15.54 μg/L, p < 0.05). The bottom
tertile of Se concentration (less than 62.2 μg/L)





Mistry et al. Association between maternal
micronutrient status, oxidative stress, and
common genetic variants in antioxidant
enzymes at 15 weeks′ gestation in nulliparous
women who subsequently develop
preeclampsia. Free Radic Biol Med, 2015
Plasma Se levels measured at gestational week
15 in 244 women who subsequently
developed preeclampsia, and compared with
472 matched normotensive controls.
Mean Se in plasma [median, IQR] was 79.0
[71.8, 87.4] μg/L in cases and 79.6 [73.1, 86.8]




Haque et al. Low serum selenium
concentration is associated with preeclampsia
in pregnant women from Bangladesh. J Trace
Elem Med Biol, 2016
Serum Se levels measured in 74 preeclampsia
patients at gestational week >/=20 (52 mild
and 22 severe preeclapmisa) and 118
normotensive pregnant women as controls
with the same gestational age.
Mean serum concentration of selenium in
preeclampsia patients was significantly lower
than that of healthy pregnant women.
Bangladesh
(da Silva et al.,
2017)
da Silva et al. Comparison of serum selenium
levels among hypertensive and normotensive
pregnant women. Hypertens Pregnancy, 2017
Serum Se levels measured at inclusion in 20
hypertensive (chronic and gestational
hypertension) women, 38 preeclamptic
women and 32 controls.
No significant difference in mean Se levels
between controls (56.4 ± 15.3μg/L),
hypertensive women (53.2 ± 15.2μg/L) and





Lewandowska et al. Serum Selenium Level in
early Healthy pregnancy as a risk marker of
pregnancy induced hypertension. Nutrients,
2019
Serum Se levels measured at gestational week
11-14. Comparison between 121 women
subsequently diagnosed with PIH and 363
matched controls.
Mean Se level significantly lower in case group
(57.5 μg/L vs. 62,9 μg/L), p = 2.6 × 10-10
Poland
Se = selenium; 1 μmol/L selenium × 79 = 1 μg/L; 80 μg/L plasma selenium equals ~100 μg/L whole blood selenium.
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E. Holmquist, A.L. Brantsæter, H.M. Meltzer et al. Science of the Total Environment 798 (2021) 149271The establishment ofMoBa and initial data collectionwas based on a
license from the Norwegian Data Protection Agency and approval from
The Regional Committees for Medical and Health Research Ethics. The
MoBa cohort is now based on regulations related to the Norwegian
Health Registry Act. The current study was approved by The Regional
Committee for Medical and Health Research Ethics (2015/2425/Rek
sør-øst A).
This study includeswomenwith singleton gestationswho gave birth
to a live-born baby at gestationalweek22–42 andwhohadfilled in both
Q1 and the FFQ (n= 82,828). Only a woman's first pregnancy enrolled
in MoBa was included. Women with hypertension before pregnancy,
chronic renal disease, systemic lupus erythematosus or any kind of dia-
betes were excluded. We also excluded women with reported energy
intake less than 4500 kJ per day or more than 20,000 kJ per day, since
these values were assumed to represent invalid reporting (Meltzer
et al., 2008). This resulted in a study population of n = 69,972 (85% of
eligible) for analysis of selenium intake. A severe form of preeclampsia
might cause a woman from refraining from another pregnancy or
might impact her behavior, e.g. to consume (more) supplements in
order to prevent recurrence of disease, introducing a possibility of re-
verse causality. Therefore, analyses were performed for all women and
for primiparas separately. Data on blood selenium status was available
for n = 2999 MoBa participants in the Norwegian EnvironmentalFig. 1. Flowchart of the study population.
* The current FFQ was introduced in 2002, explaining the large drop in numbers from box 2 to
4
Biobank (Caspersen et al., 2019), resulting in a study sample of n =
2572 for analysis of selenium status (Fig. 1).
2.2. Selenium intake from diet and supplements
Estimated dietary selenium intake during the first half of pregnancy
was based on the MoBa FFQ, designed to record dietary habits and in-
take of supplements during the first half of pregnancy. Women were
asked to report how often per day, week, or month they consumed dif-
ferent food items, dishes and beverages. The PDF of the FFQ is available
at the MoBa homepage (Norwegian Institute of Public Health, 2021).
Food frequencies were converted into amounts (μg/day) using standard
portion sizes, and energy and nutrient intakeswere calculated using the
Norwegian Food Composition Table and FoodCalc (Lauritsen, 1998).
Registered selenium supplements contained one or more forms of sele-
nium, including inorganic selenite or selenate, selenomethionine, Se-
methylselenocysteine or selenised yeast, which differ in their impact
on blood selenium concentration (Niedzielski et al., 2016). Therefore,
intake was estimated and analysed separately for selenium originating
from inorganic and organic supplements (Sigrist et al., 2012).
A validation study of the FFQ, using a four-day weighed food diary
and several biological markers as referencemethods, has demonstrated
that the MoBa FFQ is a valid tool for assessing dietary intake of energy,3.
Fig. 2. Sources of selenium from food, percent of contribution.
E. Holmquist, A.L. Brantsæter, H.M. Meltzer et al. Science of the Total Environment 798 (2021) 149271nutrients and food in the first half of pregnancy (Brantsaeter et al.,
2008).
2.3. Whole-blood selenium concentrations
A MoBa subgroup was included into the Norwegian Environmental
Biobank, established by the Norwegian Institute of Public Health
(Caspersen et al., 2019). Inclusion criteria for the Norwegian Environ-
mental Biobankwere available whole blood, urine and plasma samples,
available genetic data and available data from the first six MoBa ques-
tionnaires and the fathers' questionnaire. A total of 2999 women met
these criteria (Caspersen et al., 2019). Whole blood was collected in
heparin tubes and shipped in a vacutainer, unrefrigerated, by ordinary
mail for long-term freezing at −20 °C at a central biorepository
(Paltiel et al., 2014; Ronningen et al., 2006). Selenium analyses were
conducted at Lund University, Sweden, by inductive coupled plasma
mass spectrometry (ICP-MS; iCAP Q, Thermo Fisher Scientific, Bremen,
GmbH) equippedwith a collision cellwith kinetic energy discrimination
and helium that served as the collision gas. The detection limit was 3.2
μg/L and the coefficient of variation was 1.5%. The analytical accuracy
was verified using certified reference materials, i.e., Seronorm Trace el-
ementsWhole Blood L-1 and L-2 (SEROAS, Billingstad, Norway). The re-
sults obtained (mean± SD)were 56.1± 5.7 μg/L for L-1 (Lot 1,103,128,
N=205), compared to the recommended level of 59 (35–83) μg/L, and
116±1.5 μg/L for L-2 (Lot 1,103,129,N=205), compared to the recom-
mended level of 112 (66–158) μg/L (Caspersen et al., 2019). Selenium
was analysed in whole blood, since this reflects both current status
and uptake, while plasma/serum selenium levels only reflect short-
term status (Thomson, 2004). Plasma selenium concentrations above
80 μg/L (~100 μg/L whole-blood selenium) are considered to be ade-
quate (Thomson, 2004) while Hurst et al. found that in non-pregnant
women and men a plasma selenium concentrations up to 124 μg/L
still maximizes selenoprotein P concentrations (Hurst et al., 2010).
2.4. Pregnancy-induced hypertensive disorders
The main outcome was PIHD, with sub-analyses for PIH and pre-
eclampsia. PIHD data were obtained from the MBRN, based on forms
completed by midwives after birth. The form has tick-boxes for PIH, as
follows; mild preeclampsia; severe preeclampsia; preeclampsia with
onset before gestational week 34; the haemolysis, elevated liver en-
zymes and low platelet count (HELLP) syndrome; and eclampsia. PIHD
was defined as any of these diagnoses. Sub-analyses were performed
for women diagnosed with PIH, mild preeclampsia, and severe pre-
eclampsia (including any of the following: severe preeclampsia, early
onset preeclampsia, HELLP syndrome or eclampsia).
2.5. Covariates
Maternal age at delivery was obtained from the MBRN and catego-
rized as <25, 25–29, 30–34 or > 34 years. Pre-pregnancy body mass
index (BMI) was calculated from height and weight self-reported in
Q1 and categorized according to theWHO classification as underweight
(<18.5 kg/m2), normal-weight (18.5 to 24.9 kg/m2), overweight (25 to
29.9 kg/m2) or obese (≥30 kg/m2). Maternal education reported in Q1
was categorized into three categories (≤ 12 years, 13–16 years, ≥ 17
years). Smoking habits during pregnancy reported in Q1 were catego-
rized as non-smoker, occasional smoker or daily smoker. Alcohol con-
sumption and persistent nausea reported in the FFQ were both
applied as dichotomized variables (yes or no). Previous studies in
MoBa and elsewhere have shown that healthy dietary patterns are asso-
ciatedwith lower risk of preeclampsia (Brantsaeter et al., 2009); we ad-
justed for dietary fibre intake (g/day) as an overall marker of healthy
diet. Finally, we adjusted for total energy intake. Seleniumand iodine in-
takes from food correlate (rho=0.57) and iodine intake has been found
to be non-linearly associated with preeclampsia (Abel et al., 2020).5
Iodine intake, divided into quintiles, was therefore added as a con-
founder. Missing covariate values was treated as a category of its own,
except for iodine intake, for which only 76 women had missing data.
These women were excluded from the analyses.
2.6. Statistical analyses
The statistical analyses were performed using IBM SPSS Statistics
version 25.0. All p-values were two-sided and values <0.003 were con-
sidered significant after Bonferroni correction (0.05 / (4 exposures ∗ 4
outcomes)). Differences in median selenium intake from diet and sele-
nium status according to maternal characteristics were studied with
the Kruskal-Wallis test. Differences in frequency of selenium-
containing supplement intake (both inorganic and organic) were stud-
ied with the Chi-Square test. Prior to analysis, selenium intake and sele-
nium status variables were standardised. The logistic regressionmodels
with standardised selenium intake from diet and supplements as expo-
sures were adjusted for the following pre-defined covariates: maternal
age and BMI, nausea, smoking during pregnancy, alcohol consumption,
total energy intake, fibre intake, iodine intake and mutual adjustment
for selenium source (diet, organic supplements, inorganic supple-
ments). Analyses were performed in the whole group as well as in pri-
miparas only. To test for possible threshold effects and non-linear
associations, a sensitivity analysis with exposure in the form of deciles
of dietary selenium intake was performed. The decile closest to the rec-
ommendeddaily intake (RDI) of 60 μg/day, decile sevenwith amean se-
lenium intake of 62 μg/day, was used as the reference group. The
threshold model was adjusted for the same covariates as the model
for selenium intake as a continuous variable. The regression models
with standardised selenium concentration in whole blood as exposure
were adjusted for maternal age and BMI, nausea, smoking during preg-
nancy and alcohol consumption.
3. Results
3.1. Sources of dietary selenium intake
Fig. 2 shows dietary selenium sources. Bread, pasta, rice, cereals and
grains accounted together for around one-third (34%) of the selenium
E. Holmquist, A.L. Brantsæter, H.M. Meltzer et al. Science of the Total Environment 798 (2021) 149271intake. Other important sourceswere fish and seafood, contributing 23%
of the total intake, as well as eggs and dairy products. No foods are for-
tified with selenium in Norway.
3.2. Maternal characteristics in relation to dietary selenium intake and
selenium status
Selenium intake levels, whole-blood selenium concentrations and
supplement use according to maternal characteristics are shown in
Table 3. Study participants had a median dietary selenium intake of 53
(IQR 44–62) μg /day, which can be compared to the RDI of 60 μg/day
for pregnant women (Nordic Council of Ministers, 2014). In total,
22,750 women (33%) reported intake of dietary supplements contain-
ing selenium. Among the 2572 women with whole-blood data, the me-
dian selenium concentration was 102 μg/L (IQR 89–117).
3.3. Selenium intake and pregnancy-induced hypertensive disorders
Among the 69,972 women included in the study, 5.9% (n = 4141)
were diagnosed with PIHD, 2.1% (1445) with PIH, 2.2% (1544) with
mild preeclampsia, and 1.3% (907) with severe preeclampsia. In the
37,271 primiparous women, the corresponding figures were: PIHD
7.6% (2846), PIH 2.5% (948), mild preeclampsia 2.8% (1059), and severe
preeclampsia 1.8% (655).
Neither logistic regression analyses in all women or in the primipa-
ras showed any significant associations between dietary (Table 4) or
supplemental (Table 5) selenium intake and PIHD, PIH,mild preeclamp-
sia or severe preeclampsia. The R-squaredswere low after all three sele-
nium sources were added to the adjusted models: PIHD 0.035, PIH
0.030, mild preeclampsia 0.035 and severe preeclampsia 0.020.
Threshold analyses on selenium intake divided into deciles were
performed to examine possible non-linear associations between dietary
selenium intake and PIHD. The effect estimates (ORs and 95% CIs) in-
creased for deciles with higher dietary selenium intake than the refer-
ence group closest to the RDI, but did not reach statistical significance
after Bonferroni correction (Supplementary Table 1).
3.4. Selenium status and pregnancy-induced hypertensive disorders
Among the 2572 women with whole-blood selenium concentra-
tions, 5.1% (n = 132) were diagnosed with PIHD, 2.2% (n = 57) with
PIH, 1.9% (n= 49) with mild preeclampsia, and 0.8% (n= 20) with se-
vere preeclampsia. No significant associationswere found betweenma-
ternal selenium status and PIHD, PIH, mild preeclampsia or severe
preeclampsia (Table 6).
Threshold analyses on whole-blood selenium concentrations di-
vided into quintiles were performed to examine possible non-linear as-
sociations between whole-blood selenium concentrations and PIHD.
The middle quintile was used as reference group (mean whole-blood
selenium concentration in this group was 102 μg/L). The analyses did
not show any statistically significant associations between quintiles of
whole-blood selenium concentrations and PIHD suggesting that there
are no threshold effects (Supplementary Table 2).
4. Discussion
To the best of our knowledge, this study is the first to examine the
associations between dietary selenium intake and PIHD, PIH and pre-
eclampsia in a population-based cohort, aswell as themost comprehen-
sive study on whole-blood selenium concentrations in relation to PIHD.
We foundno associations between selenium intake fromdiet or supple-
ments and PIHD in this population with a median dietary selenium in-
take close to the RDI. Nor was selenium status, measured as selenium
concentration in whole blood sampled at mid-pregnancy, associated
with PIHD in this populationwith amedianwhole-blood selenium con-
centration close to the level considered adequate (Thomson, 2004).6
Previous RCTs on selenium supplementation during pregnancy have
generally been small (see Table 1). Rayman et al. (2014) studied the ef-
fect of selenium supplementation on risk markers for preeclampsia in
230 UK pregnant women, randomised to 60 μg/day of selenium
(enriched yeast) or placebo from 12 to 14 weeks of pregnancy until de-
livery. In participants with low selenium status at baseline, the median
serum concentration of soluble vascular endothelial growth factor
receptor-1 (sFlt-1) was significantly lower in the selenium-treated
group than in the placebo group at gestational week 35. sFlt-1 is an
anti-angiogenic factor, linked to increased risk of preeclampsia. When
the analyses were adjusted for baseline selenium concentration and
haematocrit, selenium treatment significantly reduced the odds of ei-
ther preeclampsia or PIH (OR 0.350, 95% CI 0.126, 0.974; 0 = 0.044)
(Rayman et al., 2015; Rayman et al., 2014). Another RCT including 100
pregnant women in China with high risk of PIH, randomised to 100 μg
selenium/day or placebo, found that selenium supplementation was
significantly associated with decreased PIH incidence (Han and Zhou,
1994). Contrary to these findings, a RCT in 166 pregnant Iranian
women randomised to 100 μg selenium/day or placebo did not show
any difference in preeclampsia incidence between the groups (Tara
et al., 2010). One hypothesis is that selenium supplementation only in-
fluences preeclampsia risk in populations with low selenium status
(Rayman, 2000). In the UK, where several of the previous supplementa-
tion studies have been performed, population selenium levels are low
(Ghaemi et al., 2013; Rayman et al., 2015; Tara et al., 2010), which
might explain the difference in findings between those studies and
the current study (Tables 1 and 2). Another explanation might be the
source of dietary selenium. The availability of dietary selenium depends
on the conversion of selenium within tissues to its metabolically active
forms (e.g., its incorporation into GSHPx or 5′-deiodinase) and differs
considerably for different selenium sources (Fairweather-Tait et al.,
2010). In this study population almost a quarter of all dietary selenium
was consumed in form of seafood/fish while seafood consumption is
much lower in most other populations.
For adequate enzyme function, selenium concentrations need to be
in the range 80–95 μg/L plasma (Thomson, 2004) corresponding to
~100–120 μg/L whole blood. Previous studies on selenium status have
suggested a threshold effect at plasma selenium >95 μg/L for reducing
preeclampsia incidence (Vanderlelie and Perkins, 2011). In our study,
with a median whole blood selenium concentration of 102 μg/L, most
women's selenium status could thus be regarded as sufficient which is
also supported by the selenium intake close to the recommended intake
for pregnant women (Nordic Council of Ministers, 2014). As pregnancy
is a time of rapid development with well-coordinated steps of develop-
ment taking place at defined time points, selenium status might be es-
pecially of interest in times of possible oxidant challenge, e.g. at
initiation of intervillous blood flow around pregnancy week 8–10.
Thus, the timing of selenium supplementation in different studies
might impair the comparability with results from the current study.
We found no association between selenium status and risk of PIHD,
which is in line with earlier studies (da Silva et al., 2017; Mistry et al.,
2015). Mistry et al. analysed plasma selenium status at gestational
week 15 in 244 women who subsequently developed preeclampsia,
compared to 472 matched normotensive controls, finding no associa-
tion (Mistry et al., 2015). Contrasting with these results, other studies
have shown an association between low selenium levels before preg-
nancy (Rayman et al., 2003), as well as in early and mid-pregnancy,
and increased risk of developing PIH and preeclampsia (Ghaemi et al.,
2013; Lewandowska et al., 2019). Rayman et al. analysed selenium con-
centrations in toenail clippings from 106 pregnant women, reflecting
pre-pregnancy selenium status, finding that almost half of the pre-
eclamptic subjects, but only around one-eighth of the controls, were
in the lowest tertile of toenail selenium (Rayman et al., 2003). All re-
maining samples were equally distributed between the middle and
top tertile, suggesting a threshold effectwith the lowest selenium tertile
being associated with the greatest risk of preeclampsia (Rayman et al.,
Table 3
Dietary selenium intake and selenium concentrations, by maternal characteristics, in 69,972 participants in the Norwegian Mother, Father and Child Cohort Study (2002-2008).
Selenium from food, μg/day Selenium concentration in whole
blood, μg/L








pb n % Median
(IQRa)
pb n % n % pb
All women 69,972 100 53 (44-62) 2572 100 102 (89-117) 22,750 33 47,222 67
Age at delivery, years <25 8077 12 50 (41-62) <0.001 216 8 98 (86-111) 0.001 2368 29 5708 71 <0.001
25-29 23,774 34 52 (43-62) 920 36 102 (88-116) 7869 33 15,905 67
30-34 29,672 42 53 (45-63) 1155 45 102 (90-118) 9711 33 19,961 67
>34 8449 21 54 (46-64) 281 11 105 (91-121) 2801 33 5648 67
Maternal education <13 21,657 31 51 (42-62) <0.001 654 25 100 (86-114) <0.001 6143 28 15,514 72 <0.001
13-16 29,050 42 53 (44-62) 1224 48 101 (88-116) 9845 34 19,205 66
>16 17,763 25 54 (46-64) 638 25 107 (94-122) 6297 36 11,466 65
Missing 1502 2 51 (42-62) 56 2 100 (87-116) 465 31 1037 69
Pre-pregnancy BMI,
kg/m2
<18.5 2096 3 53 (44-64) <0.001 81 3 104 (90-116) 0.05 723 34 1373 66 <0.001
18,6-24,9 45,217 65 53 (45-63) 1666 65 102 (91-118) 15,034 33 30,183 67
24,9-29,9 14,654 21 52 (43-61) 601 23 100 (88-115) 4587 31 10,067 69
≥30 6209 9 51 (42-61) 179 7 101 (86-116) 1898 31 4311 69
Missing 1796 3 53 (44-62) 45 2 101 (93-114) 508 28 1288 72
Parity 0 37,231 53 52 (43-62) <0.001 1475 57 104 (90-119) <0.001 13,543 36 23,688 64 <0.001
>0 32,684 47 52 (45-63) 1096 100 (88-114) 9187 28 23,497 71
Nausea at FFQ response No 61,992 89 53 (44-62) <0.001 2291 89 102 (90-118) 0.001 20,214 33 41,778 67 0.14
Yes 7980 11 52 (42-62) 281 11 97 (86-113) 2536 32 5444 68
Smoking Never 63,934 91 53 (44-62) <0.001 2401 93 102 (89-118) 0.001 21,079 33 42,855 67 <0.001
Occasionally 1889 3 52 (43-63) 62 2 99 (90-114) 559 30 1330 70
Daily 3752 5 51 (42-62) 99 4 95 (85-107) 1006 27 2746 73
Missing 397 1 52 (43-62) 10 0.4 97 (90-114) 106 27 291 73
Alcohol consumption No 62,207 89 53 (44-62) <0.001 2267 88 102 (89-117) 0.03 20,105 32 42,102 68 0.002
Yes 7765 11 54 (46-64) 305 12 104 (91-120) 2645 34 5120 66
Energy intake tertiles <8398 23,334 33 44 (37-50) <0.001 890 35 103 (90-118) 0.26 7538 32 15,796 68 0.55
8398-10,468 23,326 33 53 (46-60) 867 34 102 (89-117) 7621 33 15,705 67
>10,468 23,312 33 63 (55-73) 815 32 101 (89-116) 7591 33 15,721 67
Fibre intake, tertiles <25.7 23,329 33 43 (37-51) <0.001 852 33 101 (88-116) 0.04 7350 32 15,979 68 <0.001
25.7-33.9 23,331 33 53 (46-60) 903 36 102 (89-117) 7643 33 15,688 67
>33.9 23,312 33 63 (55-72) 817 32 104 (90-118) 7757 33 15,555 67
Iodine intake, quintiles <81.6 13,995 20 42 (35-49) <0.001 500 19 101 (87-118) 0.46 4580 33 9415 67 0.29
81.6-108.4 13,994 20 49 (42-56) 542 21 103 (90-118) 4568 33 9426 67
108.5-134.8 13,995 20 52 (45-60) 501 19 102 (90-117) 4559 33 9436 67
134.9-174.0 13,994 20 57 (50-65) 539 21 103 (90-117) 4545 32 9449 68
>174.0 13,994 20 65 (56-75) 490 19 101 (88-116) 4498 32 9496 68
Selenium
supplementation
No 47,222 67 53 (44-62) 0.002 1677 65 100 (87-115) <0.001
Yes 22,750 33 53 (44-63) 895 35 106 (94-121
Abbreviations: BMI – Body Mass Index; FFQ – Food Frequency Questionnaire.
a IQR = 25th–75th percentile.
b p-Value obtained with Mann-Whitney U test for 2 groups and with Kruskal-Wallis test for >2 groups.
Table 4
Association betweenmaternal dietary selenium intake and pregnancy-induced hyperten-
sive disorders (PIHD).
n Unadjusted Adjusteda
% of all ORb (95% CI) p ORb (95% CI) p
All women 69,972
PIHD 4141 5.9 0.98 (0.95,1.02) 0.30 1.03 (0.98,1.08) 0.29
PIH 1445 2.1 1.04 (0.99,1.10) 0.14 1.07 (0.99,1.16) 0.09
Mild PE 1544 2.2 0.96 (0.91,1.01) 0.08 0.99 (0.92,1.07) 0.87
Severe PE 907 1.3 0.95 (0.89,1.02) 0.13 1.02 (0.92,1.12) 0.73
Primiparas 37,271 53.3
PIHD 2846 7.6 1.05 (0.97,1.04) 0.83 1.02 (0. 97,1.08) 0.44
PIH 948 2.5 1.07 (1.00,1.14) 0.04 1.10 (1.00,1.21) 0.046
Mild PE 1059 2.8 0.95 (0.90,1.01) 0.12 0.96 (0.87,1.05) 0.33
Severe PE 655 1.8 0.97 (0.92,1.08) 0.91 1.04 (0.93,1.16) 0.54
Daily dietary intake of selenium from food and odds ratios (OR) for any pregnancy-in-
duced hypertensive disorders (PIHD), pregnancy-induced hypertension (PIH), mild pre-
eclampsia (mild PE) and severe preeclampsia (severe PE) in all subjects and in
primiparous women only, analysed with logistic regression.
a Adjusted formaternal age, education, BMI, nausea, smokingduringpregnancy, alcohol
consumption, total energy intake, fibre intake, iodine intake and intake of organic and in-
organic selenium from supplements.
b OR per standard deviation, 15.6 μg, of selenium intake.
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2003). Concurring with this, Lewandowska found significantly lower
serum selenium levels at gestational week 11–14 in 121 women who
were subsequently diagnosed with PIH, compared to 363matched con-
trols who remained normotensive (57.5 μg/L in cases vs. 62.9 μg/L in
controls; p = 2.6 × 10−10) (Lewandowska et al., 2019). An Iranian
nested case-control study on 650 healthy primiparous women found
that women who later developed preeclampsia had significantly lower
plasma selenium concentrations at gestational week 24–28, compared
to matched healthy controls (70.63 μg/L vs 82.03 μg/L; p = 0.009)
(Ghaemi et al., 2013). Moreover, being in the bottom selenium status
tertile was associated with higher risk of developing preeclampsia
(Ghaemi et al., 2013). While our study does not support these results,
the difference in biological material, toenail clippings and plasma, com-
pared to whole blood in our study, lowers the studies' comparability.
We chose to analysewhole-blood selenium since it reflects both current
status and uptake, while plasma/serum selenium only reflects short-
term status (Maleki et al., 2011; Thomson, 2004).
Case-control studies have found lower serum and plasma selenium
levels in preeclamptic women than in healthy women (Atamer et al.,
2005; Maleki et al., 2011), suggesting a higher demand for selenium in
preeclamptic pregnancies (Maleki et al., 2011). On the other hand, a
Table 5
(a) Association betweenmaternal inorganic selenium supplement intake and pregnancy-induced hypertensive disorders (PIHD) and (b) association between maternal organic selenium
supplement intake and pregnancy- induced hypertensive disorders (PIHD).
a
Supp. users Non-users Unadjusted Adjusteda
N (%) N (%) ORb (95% CI) p ORb (95% CI) p
All women 20,213 (29) 49,759 (71)
PIHD 1186 (5.9) 2955 (5.9) 1.01 (0.98,1.04) 0.54 1.01 (0. 98,1.05) 0.42
PIH 387 (1.9) 1058 (2.1) 0.97 (0.92,1.02) 0.22 0.97 (0.91,1.02) 0.21
Mild PE 479 (2.3) 1065 (2.1) 1.06 (1.01,1.11) 0.01 1.07 (1.02,1.12) 0.004
Severe PE 257 (1.3) 650 (1.3) 1.01 (0.95,1.08) 0.79 1.01 (0.95,1.07) 0.82
Primiparas 12,174 (33) 25,057 (67)
PIHD 889 (7.3) 1957 (7.8) 0.99 (0.95,1.02) 0.45 0.99 (0. 96,1.03) 0.66
PIH 291 (2.4) 657 (2.6) 0.98 (0.92,1.04) 0.44 0.97 (0.91,1.04) 0.42
Mild PE 346 (2.8) 713 (2.8) 1.01 (0.96,1.07) 0.73 1.02 (0.97,1.09) 0.42
Severe PE 202 (1.7) 453 (1.8) 0.98 (0.91,1.05) 0.56 0.99 (0.92,1.07) 0.73
b
Supp. users Non-users Unadjusted Adjusteda
N (%) N (%) ORb (95% CI) p ORb (95% CI) p
All women 3202 (5) 66,770 (95)
PIHD 166 (5.2) 3975 (6.0) 0.98 (0.94,1.01) 0.22 0.98 (0.95,1.02) 0.37
PIH 54 (1.7) 1391 (2.1) 0.97 (0.91,1.03) 0.30 0.97 (0.91,1.04) 0.39
Mild PE 55 (1.7) 1489 (2.2) 0.95 (0.89,1.02) 0.13 0.95 (0.89,1.02) 0.13
Severe PE 47 (1.5) 860 (1.3) 1.02 (0.96,1.08) 0.3 1.02 (0.96,1.09) 0.45
Primiparas 1794 (5) 35,437 (95)
PIHD 114 (6.4) 2732 (7.7) 0.97 (0.93,1.02) 0.22 0.98 (0.94,1.02) 0.32
PIH 37 (2.1) 911 (2.6) 0.98 (0.92,1.05) 0.64 0.99 (0.92,1.06) 0.67
Mild PE 40 (2.2) 1019 (2.9) 0.95 (0.88,1.03) 0.18 0.95 (0.88,1.03) 0.23
Severe PE 29 (1.6) 626 (1.8) 0.97 (0.89,1.06) 0.54 0.98 (0.90,1.07) 0.68
Daily intake of selenium from inorganic (a) and organic (b) supplements and odds ratios (OR) for any pregnancy-induced hypertensive disorders (PIHD), pregnancy induced hypertension
(PIH), mild preeclampsia (mild PE) and severe preeclampsia (severe PE) in all subjects and in primiparous women only, analysed with logistic regression.
a Adjusted for maternal age, education, BMI, nausea, smoking during pregnancy, alcohol consumption, total energy intake, fibre intake, iodine intake and dietary selenium intake, and
mutually adjusted for the other selenium supplement source.
b OR per standard deviation of the intake: 32.9 μg for inorganic selenium supplements and 10.5 μg for organic selenium supplements.
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women with preeclampsia or PIH, as well as 32 normotensive women,
finding that serum selenium levels did not differ significantly in the
two groups (da Silva et al., 2017).
4.1. Strengths and limitations
To the best of our knowledge, this is the most comprehensive study
on selenium intake and PIHD and thefirst to study selenium intake from
diet. It is important to note that selenium intakewas only assessed once,
inmid-pregnancy, and the results thus reflect intake during thefirst half
of pregnancy. Hence, we cannot draw any conclusions on the impact ofTable 6
Association between maternal whole blood selenium concentration and pregnancy- in-
duced hypertensive disorders (PIHD).
Unadjusted Adjusteda
n cases (%) ORb (95% CI) p ORb (95% CI) p
All women 2572
PIHD 132 (5.1) 1.00 (0.84,1.19) 0.10 1.03 (0.86,1.22) 0.78
PIH 57 (2.2) 0.98 (0.76,1.28) 0.90 0.98 (0.75,1.29) 0.91
Mild PE 49 (1.9) 0.99 (0.74,1.31) 0.92 1.03 (0.79,1.36) 0.82
Severe PE 20 (0.8) 1.04 (0.68,1.58) 0.86 1.06 (0.72,1.56) 0.78
Selenium concentration and odds ratios for pregnancy-induced hypertensive disorders
(PIHD), pregnancy-induced hypertension (PIH), mild and severe preeclampsia (mild PE
and severe PE), analysed with logistic regression.
a Adjusted for maternal age, education, BMI, nausea, alcohol consumption, smoking
during pregnancy.
b OR per standard deviation, 23.5 μg/L, of selenium concentration in blood.
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selenium intake at other stages of pregnancy. Due to the observational
design of this study, residual confounding cannot be ruled out, although
the comprehensive dataset allowed us to account for possible
confounders.
This is also the largest study on selenium status in whole blood and
PIHD. However, since one inclusion criterion for participation in the
Norwegian Environmental Biobank Study was to have answered the
first six MoBa questionnaires, the subgroup of women with data on
whole-blood selenium concentrations is a highly selected group. The
subgroup included a higher proportion of non-smokers and highly edu-
cated women, compared with the whole MoBa population (Caspersen
et al., 2019), and their PIHD incidence was 5.1%, compared to 5.9% in
the selenium intake study group. Thus, the generalizability of the asso-
ciation between blood selenium concentrations and PIHD may be lim-
ited due to selection bias.
Monitoring of selenium status in representative population groups
should be encouraged.
Previous research suggests that genotype, both for seleno-proteins
and related pathways, must be taken into account when assessing the
impact of selenium intake or status on preeclampsia risk. Further stud-
ies combining data on selenium intake and status, seleno-protein activ-
ity and genotype are needed in order to understand the impact of
selenium on PIHD risk.5. Conclusions
Our results do not support a protective effect of selenium intake or
status in regard to PIHD in this populationwithmedian selenium intake
and levels close to those recommended for pregnant women.
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